PE20071141A1 - Derivados de metastina - Google Patents

Derivados de metastina

Info

Publication number
PE20071141A1
PE20071141A1 PE2006001686A PE2006001686A PE20071141A1 PE 20071141 A1 PE20071141 A1 PE 20071141A1 PE 2006001686 A PE2006001686 A PE 2006001686A PE 2006001686 A PE2006001686 A PE 2006001686A PE 20071141 A1 PE20071141 A1 PE 20071141A1
Authority
PE
Peru
Prior art keywords
tyr
trp
phe
leu
val
Prior art date
Application number
PE2006001686A
Other languages
English (en)
Spanish (es)
Inventor
Taiji Asami
Naoki Nishizawa
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37846230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20071141(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20071141A1 publication Critical patent/PE20071141A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
PE2006001686A 2005-12-22 2006-12-21 Derivados de metastina PE20071141A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005370388 2005-12-22
JP2006275843 2006-10-06

Publications (1)

Publication Number Publication Date
PE20071141A1 true PE20071141A1 (es) 2008-01-07

Family

ID=37846230

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001686A PE20071141A1 (es) 2005-12-22 2006-12-21 Derivados de metastina

Country Status (29)

Country Link
US (1) US7960348B2 (enExample)
EP (1) EP1963362B1 (enExample)
JP (2) JP4653840B2 (enExample)
KR (1) KR101368607B1 (enExample)
AR (1) AR058584A1 (enExample)
AU (1) AU2006328333B2 (enExample)
BR (1) BRPI0619399B8 (enExample)
CA (1) CA2634647C (enExample)
CR (1) CR10019A (enExample)
CY (1) CY1112353T1 (enExample)
DK (1) DK1963362T3 (enExample)
ES (1) ES2375038T3 (enExample)
GE (1) GEP20115356B (enExample)
HR (1) HRP20110851T1 (enExample)
IL (1) IL190888A (enExample)
JO (1) JO2799B1 (enExample)
MA (1) MA30060B1 (enExample)
ME (1) ME01015B (enExample)
MY (1) MY151967A (enExample)
NO (1) NO341879B1 (enExample)
NZ (1) NZ568322A (enExample)
PE (1) PE20071141A1 (enExample)
PL (1) PL1963362T3 (enExample)
PT (1) PT1963362E (enExample)
RS (1) RS52007B (enExample)
RU (1) RU2430107C2 (enExample)
SI (1) SI1963362T1 (enExample)
TW (1) TWI386417B (enExample)
WO (1) WO2007072997A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004063221A1 (ja) 2002-12-26 2004-07-29 Takeda Pharmaceutical Company Limited メタスチン誘導体およびその用途
US7754220B2 (en) 2003-03-12 2010-07-13 Takeda Pharmaceutical Company Limited Methods of inhibiting secretion of follicle-stimulating hormone and testosterone
WO2006001499A2 (en) 2004-06-25 2006-01-05 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
AR058584A1 (es) 2005-12-22 2008-02-13 Takeda Pharmaceutical Derivados de metastina y uso de los mismos
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
US20090093615A1 (en) * 2005-12-22 2009-04-09 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
JO3048B1 (ar) * 2006-10-25 2016-09-05 Takeda Pharmaceuticals Co مشتقات متاستين واستخدامها
US20110118172A1 (en) * 2008-04-24 2011-05-19 Takeda Pharmaceutical Company Limited Metastin derivative and use thereof
WO2010013762A1 (ja) 2008-07-30 2010-02-04 武田薬品工業株式会社 メタスチン誘導体およびその用途
GEP20146001B (en) * 2008-12-29 2014-01-10 Takeda Pharmaceuticals Co Cancer prophylactic/therapeutic agent
MX2012006441A (es) * 2009-12-22 2012-06-28 Takeda Pharmaceutical Formulacion de liberacion sostenida.
EP2585091B1 (en) 2010-06-25 2014-09-10 Takeda Pharmaceutical Company Limited Sustained-release formulation comprising a metastin derivative
EP2755690B1 (en) 2011-08-04 2020-04-01 Merck Sharp & Dohme B.V. Kisspeptide-pentasaccharide conjugates
EP2873455B1 (en) 2012-07-12 2021-07-07 Takeda Pharmaceutical Company Limited Method for manufacturing microcapsule powder
WO2015112703A1 (en) * 2014-01-22 2015-07-30 The Johns Hopkins University Compositions and methods for treating diabetes
JP6253146B2 (ja) * 2014-02-04 2017-12-27 国立大学法人山口大学 新規なペプチド誘導体及びこれを含有する医薬
WO2018060501A2 (en) 2016-09-30 2018-04-05 Myovant Sciences Gmbh Methods of treating uterine fibroids and endometriosis
CA3038865A1 (en) * 2016-09-30 2018-04-05 Myovant Sciences Gmbh Methods of treating female infertility
CN116813705A (zh) * 2017-07-05 2023-09-29 凯惠科技发展(上海)有限公司 一种肽类化合物、其应用及含其的组合物
BR112022023937A2 (pt) 2020-05-29 2022-12-27 Myovant Sciences Gmbh Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina
WO2025217074A1 (en) * 2024-04-08 2025-10-16 Radionetics Oncology, Inc. Kisspeptin receptor (kiss1r) targeted therapeutics and uses thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL74827A (en) 1984-05-21 1989-06-30 Salk Inst For Biological Studi Peptides active as gnrh antagonists and pharmaceutical compositions containing them
MX9100717A (es) 1990-08-24 1992-04-01 Syntex Inc Antagonistas de la bradiquinina
JPH09169735A (ja) 1995-10-19 1997-06-30 Takeda Chem Ind Ltd キノリン誘導体、その製造法および用途
CA2229201A1 (en) 1995-10-19 1997-04-24 Satoshi Sasaki Quinoline derivatives, their production and use
AU2382097A (en) 1996-04-19 1997-11-12 Novo Nordisk A/S Compounds with growth hormone releasing properties
CA2283299A1 (en) 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 186 human secreted proteins
JP4486187B2 (ja) 1998-10-27 2010-06-23 武田薬品工業株式会社 新規ｇ蛋白質共役型レセプター蛋白質、そのｄｎａおよびそのリガンド
US6528054B1 (en) 1998-12-28 2003-03-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
MXPA01013367A (es) 1999-06-28 2002-07-02 Basf Ag Metodo para la prevencion del crecimiento tumoral.
EP1200553B1 (en) 1999-08-02 2009-07-15 Archer-Daniels-Midland Company Metabolic engineering of amino acid production
AU1889101A (en) 1999-12-17 2001-06-25 Takeda Chemical Industries Ltd. Process for producing kiss-1 peptide
AU2001261007A1 (en) 2000-03-29 2001-10-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO2001075104A1 (fr) 2000-03-30 2001-10-11 Takeda Chemical Industries, Ltd. Nouvelle proteine, adn codant pour celle-ci, et son procede de production
US7834141B1 (en) 2000-03-31 2010-11-16 Theresa Siler-Khodr Non-mammalian GnRH analogs and uses thereof in tumor cell growth regulation and cancer therapy
RU2311920C2 (ru) 2000-09-20 2007-12-10 Корикса Корпорейшн Композиции и способы для лечения и диагностики рака легких
JP2003026601A (ja) 2000-11-29 2003-01-29 Takeda Chem Ind Ltd 医薬組成物およびその製造法
JP2002320496A (ja) 2001-02-26 2002-11-05 Takeda Chem Ind Ltd 新規マウス型ＫｉＳＳ−１レセプタータンパク質およびそのＤＮＡ
WO2002085399A1 (fr) 2001-04-20 2002-10-31 Takeda Chemical Industries, Ltd. Preparations contenant un peptide
WO2002092829A1 (en) 2001-05-17 2002-11-21 Takeda Chemical Industries, Ltd. Process for producing peptide
DE60219645T2 (de) * 2001-09-19 2007-08-09 Takeda Pharmaceutical Co. Ltd. Antikörper gegen metastin und dessen verwendung zur diagnose von schwangerschaft
AU2003201854A1 (en) * 2002-01-11 2003-07-30 Takeda Chemical Industries, Ltd. PROCESS FOR PRODUCING KiSS-1 PEPTIDE
JP2003300906A (ja) 2002-04-12 2003-10-21 Daiichi Fine Chemical Co Ltd がん転移抑制因子の安定化
MXPA05004380A (es) 2002-10-25 2005-11-23 Paradigm Therapeutics Ltd Mamiferos gpr54 knock out y metodos de investigacion que los utilizan.
WO2004063221A1 (ja) 2002-12-26 2004-07-29 Takeda Pharmaceutical Company Limited メタスチン誘導体およびその用途
JP4804714B2 (ja) 2002-12-26 2011-11-02 武田薬品工業株式会社 メタスチン誘導体およびその用途
US6800611B2 (en) * 2003-01-06 2004-10-05 Takeda Chemical Industries, Ltd. Metastin derivatives and their use
KR100595364B1 (ko) 2003-02-20 2006-07-03 재단법인 목암생명공학연구소 Ｌｋ8 단백질을 유효성분으로 포함하는 항암제
US7754220B2 (en) * 2003-03-12 2010-07-13 Takeda Pharmaceutical Company Limited Methods of inhibiting secretion of follicle-stimulating hormone and testosterone
EP1464652A1 (en) 2003-04-02 2004-10-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) GPR54 receptor agonist and antagonist useful for the treatment of gonadotropin related diseases
US20050002935A1 (en) 2003-04-17 2005-01-06 Vincent Ling Use of B7-H3 as an immunoregulatory agent
US20050026224A1 (en) 2003-04-28 2005-02-03 Follettie Maximillian T. Methods and compositions for modulating G-protein coupled receptor 54
WO2004101747A2 (en) 2003-05-07 2004-11-25 The General Hospital Corporation Identification and use of gpr54 and its ligands for reproductive disorders and contraception
WO2004106289A1 (en) 2003-05-30 2004-12-09 Prozymex A/S Protease inhibitors
RU2333221C2 (ru) 2003-11-03 2008-09-10 Бейцзин Санбио Байотек Ко., Лтд. Рекомбинантный белок, обладающий противораковым действием, кодирующий его ген и его применение
CA2544473C (en) 2003-11-03 2013-08-13 Beijing Sunbio Biotech Co., Ltd. A recombinant protein having an anti-cancer effect, its encoding gene and uses thereof
WO2005095973A2 (en) 2004-03-25 2005-10-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 54 (gpr54)
WO2006001499A2 (en) * 2004-06-25 2006-01-05 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
US7725869B1 (en) * 2005-04-07 2010-05-25 Xilinx, Inc. Method and apparatus for modeling multiple instances of an electronic circuit using an imperative programming language description
WO2007084211A2 (en) 2005-11-11 2007-07-26 The General Hospital Corporation Use of gpr54 ligands for treatment of reproductive disorders, proliferative disorders, and for contraception
US20090093615A1 (en) * 2005-12-22 2009-04-09 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
US8404643B2 (en) * 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
AR058584A1 (es) 2005-12-22 2008-02-13 Takeda Pharmaceutical Derivados de metastina y uso de los mismos
US20090099334A1 (en) * 2005-12-22 2009-04-16 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
JO3048B1 (ar) 2006-10-25 2016-09-05 Takeda Pharmaceuticals Co مشتقات متاستين واستخدامها

Also Published As

Publication number Publication date
TWI386417B (zh) 2013-02-21
KR101368607B1 (ko) 2014-02-27
JP2010265311A (ja) 2010-11-25
JP2009520682A (ja) 2009-05-28
KR20080086438A (ko) 2008-09-25
CR10019A (es) 2008-07-29
JO2799B1 (en) 2014-03-15
JP4653840B2 (ja) 2011-03-16
JP5298087B2 (ja) 2013-09-25
CY1112353T1 (el) 2015-12-09
RU2430107C2 (ru) 2011-09-27
MA30060B1 (fr) 2008-12-01
CA2634647C (en) 2014-01-28
AU2006328333A1 (en) 2007-06-28
EP1963362B1 (en) 2011-08-24
BRPI0619399B1 (pt) 2019-07-09
RU2008125063A (ru) 2009-12-27
US20100331520A1 (en) 2010-12-30
BRPI0619399B8 (pt) 2021-05-25
TW200804414A (en) 2008-01-16
WO2007072997A1 (en) 2007-06-28
SI1963362T1 (sl) 2011-12-30
CA2634647A1 (en) 2007-06-28
ES2375038T3 (es) 2012-02-24
HK1120809A1 (en) 2009-04-09
NO341879B1 (no) 2018-02-12
EP1963362A1 (en) 2008-09-03
BRPI0619399A2 (pt) 2013-01-08
HRP20110851T1 (hr) 2011-12-31
US7960348B2 (en) 2011-06-14
NO20082595L (no) 2008-09-22
IL190888A0 (en) 2008-11-03
PT1963362E (pt) 2011-10-17
IL190888A (en) 2014-07-31
PL1963362T3 (pl) 2012-04-30
ME01015B (me) 2012-10-20
AU2006328333B2 (en) 2011-11-17
AR058584A1 (es) 2008-02-13
NZ568322A (en) 2010-12-24
MY151967A (en) 2014-07-31
DK1963362T3 (da) 2011-09-19
GEP20115356B (en) 2011-12-26
RS52007B (sr) 2012-04-30

Similar Documents

Publication Publication Date Title
AR058584A1 (es) Derivados de metastina y uso de los mismos
NZ600732A (en) Oxyntomodulin peptide analogue
ES2406090T3 (es) Péptidos que tienen actividad farmacológica para tratar los trastornos asociados con la alteración de la migración celular, tal como el cáncer
ES2768610T3 (es) Inhibidores macrocíclicos de las interacciones proteína/proteína PD-1/PD-L1 y CD80(B7-1)/PD-L1
GT200300142A (es) Agonistas del receptor (vpac2) del peptido activante de la adenilato ciclasa hipofisaria (pacap) y sus metodos de uso farmacologicos
EA201291362A1 (ru) Слитый белок против злокачественных новообразований
EP1548028A4 (en) SUBSTITUTED WT1 PEPTIDES
AR049572A1 (es) Moduladores del peptido 1 similar al glucagon humano y su uso en el tratamiento de la diabetes y condiciones relacionadas
MXPA03011940A (es) Ligandos del receptor de 5-ht- y sus usos.
HU217843B (hu) Paratiroid hormon (PTH) rokon polipeptidek, eljárások ezek előállítására és az ezeket tartalmazó gyógyszerek osteoporosis kezelésére
MX2009002547A (es) Composiciones terapeuticas de peptido de fusion.
DK149046B (da) Analogifremgangsmaade til fremstilling af lhrh-analoge nonapeptid- ogdecapeptidderivater eller farmaceutisk acceptable salte deraf
RU2015103816A (ru) ПРОНИКАЮЩИЕ В КЛЕТКУ ПЕПТИДЫ, МИШЕНЬЮ КОТОРЫХ ЯВЛЯЕТСЯ eIF4E
MX2022014506A (es) Cisteina proteasa.
ATE412412T1 (de) Derivate des 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1 -pyrazols als antagonisten des gonadotropin freisetzenden hormons (gnrh) zur anwendung in de behandlung von geschlechtshormonellen erkrankungen, wie prostata-oder gebahrmutterkrebs
US20170342107A1 (en) Melanocortin ligands and methods of use thereof
JP3801867B2 (ja) 改善された溶解特性を有する新規のｌｈｒｈアンタゴニスト
DK1417222T3 (da) Isolerede polypeptider baseret på den neutraliserende epitop af p17-proteinet fra HIV egnet til vacciner samt neutraliserende anti-p17-antistoffer, der specifikt genkender nævnte neutraliserende epitop
YU57201A (sh) 16-hidroksiestratrieni kao selektivno aktivni estrogeni
HN1999000063A (es) Combinaciones terapeuticas que comprenden un moduladir del receptor de estrogenos selectivo y hormona paratiroidea.
TWI300414B (en) Modified peptide yy and conjugates thereof
PE20050665A1 (es) ESTROGENOS SELECTIVOS DE 8ß-VINIL-ESTRA-1,3,5(10)-TRIEN-3,17ß-DIOL Y 17ß-FLUOR-9-VINIL-ESTRA-1,3,6(10)-TRIEN-3,16ALFA-DIOL
Sanz-Soler et al. Recombinant expression of mutants of the Frankenstein disintegrin, RTS-ocellatusin. Evidence for the independent origin of RGD and KTS/RTS disintegrins
WO2005072277A3 (en) Amidated parathyroid hormone fragments and uses thereof
Si et al. One-pot ligation strategy for atypical ubiquitin chains synthesis by using the trifluoroacetamidomethyl-protected isopeptide-linked Ub (Tfacm-isoUb) unit

Legal Events

Date Code Title Description
FG Grant, registration